Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Given the weaker price action, is now an opportune time to buy ZTS? Find out in our full research report, it’s free.
Originally a subsidiary of Pfizer, Zoetis (NYSE:ZTS) is an animal health company that develops and distributes medicines, vaccines, and diagnostic products for livestock and pets.
In addition to reported revenue, constant currency revenue is a useful data point for analyzing Branded Pharmaceuticals companies. This metric excludes currency movements, which are outside of Zoetis’s control and are not indicative of underlying demand.
Over the last two years, Zoetis’s constant currency revenue averaged 9% year-on-year growth. This performance was solid and shows it can expand steadily on a global scale regardless of the macroeconomic environment.
Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).
Zoetis’s five-year average ROIC was 28.7%, placing it among the best healthcare companies. This illustrates its management team’s ability to invest in highly profitable ventures and produce tangible results for shareholders.
Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.
Over the next 12 months, sell-side analysts expect Zoetis’s revenue to stall, a deceleration versus its 7% annualized growth for the past two years. This projection is underwhelming and implies its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health.
Zoetis’s positive characteristics outweigh the negatives. After the recent drawdown, the stock trades at 26.9× forward price-to-earnings (or $166 per share). Is now a good time to initiate a position? See for yourself in our in-depth research report, it’s free.
With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run – and we’re laser-focused on finding the best stocks for this upcoming cycle.
Story Continues
